Research Article





ODEWUSI Odeyinka Olufunsho, EBITIMI Cocodia, OLANIYAN  Olayinka Olaolu


ABSTRACT: Objectives: This study is designed to assess and ascertain the serum level of antinuclear antibodies (ANA) concentration and lupus erythematosus (LE) positivity in treated and untreated hypertensive patients relative to non-hyprtensive apparently healthy individuals.

Methods: This study investigated a total number of 116 subjects age between 18-70 years comprising 54 hypertensives on known anti HBP medications, 35 hypertensives not on anti HBP medications and 27 apparently healthy individuals.  Blood samples were collected from patients attending the General Out-patient Department of Federal Teaching Hospital Ido-ekiti, Ekiti State Nigeria. Blood pressure was taken from the non-dominant amusing appropriate cuff size and mercury sphygmomanometer, while, blood sample was Anti-nuclear antibodies was measured using ELISA while LE cells was ascertained with Leishman stained microscopy of defibrinated blood. Statistical analysis was done using SPSS, all values were significant at p<0.05.       

Results: Both systolic and diastolic blood pressure were observed to be significantly higher in both treated and untreated essential hypertensives compared with controls (P<0.0001). Serum ANA levels were also found to be significantly higher in untreated hypertensives compared with both treated hypertensives and controls (P<0.0001). Diastolic blood pressure correlated directly with systolic blood pressure and ANA levels in untreated hypertensives (r=0.556) (r=0.318) respectively but inversely with BMI in treated hypertensives. LE cell positivity was found to be higher in untreated hypertensives having a percentage LE test positivity of 2.9% as compared to the percentage in treated hypertensives where 1.9% were positive.

Conclusion: It was deduced that serum elevated ANA levels as well as LE positivity are also characteristics of essential hypertension. It was also found out that the possibility of LE positivity and ANA levels in essential hypertensives increases with weight, age and being of the female gender.

KEY WORDS: Essential hypertension; Antinuclear antibodies, LE cell.      


  1. Naish J and Court DS. Medical sciences (2nd ed.) 2014. p. 562

  2. Pickering GW.The natural history of hypertension. Br Med Bull 1952;8:305-309.

  3. Chobanian AV, Bakris GL, Black H. Seventh report of the Joint National Committee on  prevention, detection, evaluation, and treatment of high blood pressure. Hypertens 2003; 42:1206–52.

  4. Poulter NR, Prabhakaran D, Caulfield M. .  Hypertension. The Lancet 2015;386: 801–12.

  5. Dickson ME, Sigmund CD. "Genetic basis of hypertension: revisiting angiotensinogen". Hypertens 2006;48:14–20.

  6. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al.. The British Hypertension Society; Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society. J Hum Hypertens 2004;18:139-85.

  7. Patt H, Bandgar T, Lila A, Shah N . "Management issues with exogenous steroid therapy". Indian J Endocrinol Metab 2013; 17: 612–7. 

  8. Salamunic I . Laboratory diagnosis of autoimmune diseases-new technologies, old dilemmas. Biochem. Med j 2010; 20: 45-56.     

  9. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ . Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertens 2010; 55:500–7.

  10. Barhoumi T, Kasal D, Li M, Shbat L, Laurant P, Neves M (2011). T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertens 2011; 57:469–76.

  11. Youn J, Yu H, Lim B, Koh M, Lee J, Chang D . Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertens2013; 62: 126–33.

  12. Harrison D, Guzik T, Lob HE, Madhur MS, Marvar P, Thabet S (2011). Inflammation, immunity, and hypertension. Hypertens2011; 57:132–40.

  13. Rodriguez-Iturbe B, Franco M, Tapia E, Quiroz Y, Johnson R (2012). Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physio l2012; 39:96–103.

  14. Reece J, Campbell N. Biology (7th ed.). San Francisco: Pearson/Benjamin-Cummings. ISBN 978-0805371468. 2005:544- 48.

  15. Cervera R, Font J, Ramos-Casals M, García-Carrasco M, Rosas J, Morlà RM. Et al. . "Primary Sjögren's syndrome in men: clin.  immunol.Charact 2000.9;1:61–4. 

  16. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. "Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists". Arch.Path. Lab. Med. 2000; 124:71–81. 

  17. Klemperer P, Pollack AD, Baehr G: Pathology of disseminated lupus erythematosus. Arch Path 941; 32:569-631.

  18. Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements: the 'tart' cell and the "LE' cell. Proceedings of the Mayo Clinic.1948; 23:25-8.    

  19. Gay L and Barr J. “Laboratory procedures used in the diagnosis of systemic lupus erythematosus: a review”, Am J Med Tech 1977; 43:856–63.

  20. Tan PL, Borman GB, Wigley RD. “Testing clinical criteria for systemic lupus erythematosus in other connective tissue disorders”, Rheumato 1981; 1:147–9.

  21. Mevorach D “Systemic lupus erythematosus and apoptosis: a question of balance”, Clin Rev Allerg Immun 2003; 25:49–60.

  22. Charles PJ “Defective waste disposal: does it induce autoantibodies in SLE?”Ann of Rheum Dis 2003;62: 1–3.

  23. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control (PDF) (1st ed.). Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization. 2011. p. 38. 

  24. Tseng CH. Higher risk of hypertension in indigenous type 2 diabetic patients in Taiwan. Journals of Hypertension 2006;24:1817-21.

  25. Akilli H, Kayrak M, Bekci TT. Gender-related changes of the epicardial fat thickness and leptin in obstructive sleep apnea. Echocardiol 2014;31:411–9. 

  26. Flack  JM  ,  Sica DA,  Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, ,  an update of the International Society on Hypertension in Blacks consensus statement Hypertension aha               2010;56:780-800.

  27. Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease Part II: estimates of attributable burden. J Hum Hypertens 2006;24: 423–30.

  28. Gudbrandsson T, Hansson L, Herlitz H, Lindholm L, Nilsson LA . Immunological changes in patients with previous malignant essential hypertension. Lancet 1981;1:406–8.

  29. Odewusi O O and  Osadolor, H.B.  Interleukin 10 And 18 Levels in Essential Hypertensive subjects.  J Appl Sci Environ Manag 2019;23:819-24.

  30. Xavier RM, Yamauchi Y, Nakamura M, Tanigawa Y, Ishikura H, Tsunematsu T, . Antinuclear antibodies in healthy aging people: a prospective study. Mech. Ageing Dev 1995;78:145–54.

 To cite this article:

JODEWUSI OO, EBITIMI C, OLANIYAN OO. An assessment of antinuclear antibodies and LE cell positivity in essential hypertensive subjects. Int. J. Med. Lab. Res. 2021; 35-43.